UroGen Pharma Ltd’s recently made public that its Officer Schoenberg Mark acquired Company’s shares for reported $97574.0 on Jul 28 ’25. In the deal valued at $18.95 per share,5,149 shares were bought.
Then, Smith Jason Drew bought 7,522 shares, generating $142,542 in total proceeds.
Before that, Schoenberg Mark sold 5,162 shares. UroGen Pharma Ltd shares valued at $38,044 were divested by the Chief Medical Officer at a price of $7.37 per share. As a result of the transaction, Schoenberg Mark now holds 153,378 shares, worth roughly $2.9 million.
H.C. Wainwright upgraded its UroGen Pharma Ltd [URGN] rating to a Buy from a a Neutral in a research note published recently. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who decreased its forecast for the stock in late May from “a Buy” to “a Neutral”. Scotiabank began covering URGN with “Sector outperform” recommendation on April 16, 2025.
Price Performance Review of URGN
On Tuesday, UroGen Pharma Ltd [NASDAQ:URGN] saw its stock unchanged to $18.9. Over the last five days, the stock has gained 11.44%. UroGen Pharma Ltd shares have risen nearly 15.53% since the year began. Nevertheless, the stocks have risen 77.46% over the past one year. While a 52-week high of $19.35 was reached on 07/28/25, a 52-week low of $3.42 was recorded on 05/21/25.
Levels Of Support And Resistance For URGN Stock
The 24-hour chart illustrates a support level at 18.50, which if violated will result in even more drops to 18.10. On the upside, there is a resistance level at 19.17. A further resistance level may holdings at 19.45.
How much short interest is there in UroGen Pharma Ltd?
A steep rise in short interest was recorded in UroGen Pharma Ltd stocks on 2025-07-15, growing by 1.17 million shares to a total of 7.29 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 6.13 million shares. There was a rise of 16.02%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on August 22, 2024 when Guggenheim began covering the stock and recommended ‘”a Buy”‘ rating along with a $40 price target.
